Skip to main content

Abivax

Abivax SA is a French clinical-stage biotechnology company focused on developing therapies that modulate the immune system to treat chronic inflammatory diseases. The company operates through a single biopharmaceutical research and development segment, centered on its lead drug candidate, obefazimod. Its potential future revenue drivers stem from clinical trial progression, regulatory licensing approvals, commercialization agreements, and prospective pharmaceutical sales for autoimmune indications. Abivax concentrates its research on ulcerative colitis, Crohn's disease, and other severe inflammatory conditions, conducting advanced global clinical trials across Europe and North America. The enterprise holds a recognized position within the biopharmaceutical sector as a developer of novel small-molecule RNA modulators with anti-inflammatory properties. The company focuses strategic resources on executing late-stage Phase 3 clinical trials, securing global regulatory pathways, and expanding its intellectual property portfolio. Abivax SA is headquartered in Paris, France, and its common shares are listed on Euronext Paris alongside American Depositary Shares on the Nasdaq Global Market.

24 of the funds FundTelligence covers report a position in Abivax.

Legal name
Abivax SA
Sector
Health Care
Country
France
Funds holding it
24

Funds holding Abivax

Showing the 8 largest of 24 funds holding it.

Loading...